Sakar Healthcare Limited has informed the Exchange about Transcript
SAKAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sakar Healthcare reported strong Q4 FY26 results with revenue of INR7,109.70 lakhs (42% YoY growth), EBITDA of INR2,623.57 lakhs (67% YoY growth with 37% margins), and PAT of INR1,102.43 lakhs (91% YoY growth). For FY26, revenue stood at INR25,173.60 lakhs with PAT of INR3,048.46 lakhs (74% growth). The company is transforming into a focused oncology player with 38% of revenues now from oncology (up from 21% in FY25). Key highlights include 60+ oncology contracts signed, 125 dossiers filed globally, and 12 marketing authorizations received. The EU GMP approved Bavla facility has 29-30% capacity utilization with potential to generate INR800-1,000 crores at optimal levels. Management guided for ~40% growth in FY27 targeting INR380 crores revenue, with INR500 crores as the two-year milestone.
Strong execution with margin expansion driven by operational efficiencies. The shift to higher-margin oncology exports positions the company for sustained profitability growth, though export ramp-up timing remains uncertain due to regulatory and commercialization processes.